VEGF and MMP-9: Biomarkers for canine lymphoma

Veterinary and Comparative Oncology

Volumn 12, Issue 1, 2014, Pages 29-36

  Aresu, L ^a   Arico A ^a   Comazzi, S ^b   Gelain, M E ^b   Riondato, F ^c   Mortarino, M ^b   Morello, E ^c   Stefanello, D ^b   Castagnaro, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Canine lymphoma; MMP 9; Prognosis; VEGF

Indexed keywords

CANIS FAMILIARIS;

ANTINEOPLASTIC AGENT; CYTOKINE; GELATINASE B; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CANINE LYMPHOMA; DOG; DOG DISEASE; GENETICS; LYMPHOMA; METABOLISM; MMP-9; PATHOLOGY; PROGNOSIS;

CANINE LYMPHOMA; MMP-9; PROGNOSIS; VEGF;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; DOG DISEASES; DOGS; LYMPHOMA; MATRIX METALLOPROTEINASE 9; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892993993     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2012.00328.x     Document Type: Article

References (31)

1. Vail DM and MacEwen EG. Spontaneously occurring tumors of companion animals as model for human cancer. Cancer Investigation 2000; 18: 781-792.
2. Breen M and Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship. Chromosome Research 2008; 16: 145-154.
3. Pedersen LM, Klausen TW, Davidsen UH and Johnsen HE. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's Lymphoma. Annals of Hematology 2005; 84: 510-516.
4. Labidi SI, Ménétrier-Caux C, Chabaud S, Chassagne C, Sebban C, Gargi T, Biron P, Blay JY and Ghesquières H. Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival. Annals of Hematology 2009; 89: 25-33.
5. Sporn MB and Todaro GJ. Autocrine secretion and malignant transformation of cells. The New England Journal of Medicine 1980; 303: 878-880.
6. Ferrara N, Gerber HP and LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003; 9: 669-676.
7. Takahashi H and Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clinical Science 2005; 108: 227-241.
8. Ravitz MJ and Wenner CE. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-b. Advances in Cancer Research 1997; 71: 165-207.
9. Pasche B. Role of transforming growth factor b in cancer. Journal of Cellular Physiology 2001; 186: 153-168.
10. Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H and Ten Dijke P. The TGF-beta/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Research and Treatment 2011; 128: 657-666.
11. Ten Dijke P and Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nature Reviews Molecular Cell Biology 2007; 8: 857-869.
12. Moustakas A, Pardali K, Gaal A and Heldin HC. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunology Letters 2002; 82: 85-91.
13. Taipale J, Saharinen J and Keski-Oja J. Extracellular matrix associated transforming growth factor beta: role in cancer cell growth and invasion. Advances in Cancer Research 1998; 75: 87-134.
14. Egeblad M and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2002; 2: 161-174.
15. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2000; 2: 737-744.
16. Wolfesberger B, Tonar Z, Witter K, Guija de Arespacohaga A, Skalicky M, Walter I, Thalhammer JG and Egger GF. Microvessel density in normal lymph nodes and lymphomas of dogs and their correlation with vascular endothelial growth factor expression. Research in Veterinary Science 2008; 85: 56-61.
17. Gentilini F, Calzolari C, Turba ME, Agnoli C, Fava D, Forni M and Bergamini PF. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Leukemia Research 2005; 29: 1263-1269.
18. Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, Pastor M, Delignette ML and Fournel-Fleury C. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Veterinary Pathology 2010; 47: 414-433.
19. Gelain ME, Mazzilli M, Riondato F, Marconato L and Comazzi S. Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry. Veterinary Immunology and Immunopathology 2008; 121: 179-188.
20. Simon D, Nolte I, Eberle N, Abbrederis N, Killich M and Hirschberger J. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. Journal of Veterinary Internal Medicine 2006; 20: 948-954.
21. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Research 1993; 53: 5365-5369.
22. Aresu L, Giantin M, Morello E, Vascellari M, Castagnaro M, Lopparelli R, Zancanella V, Granato A, Garbisa S, Aricò A, Bradaschia A, Mutinelli F and Dacasto M. Matrix metalloproteinases and their inhibitors in canine mammary tumors. BMC Veterinary Research 2011; 7: 33-43.
23. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J and Favrot MC. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82: 2169-2174.
24. Hirayama K, Yokota H, Onai R, Kobayashi T, Kumata T, Kihara K, Okamoto M, Sako T, Nakade T, Izumisawa Y and Taniyama H. Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. Journal of Comparative Pathology 2002; 127: 249-256.
25. Yonemaru K, Sakai H, Murakami M, Yanai T and Maseqi T. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors. Veterinary Pathology 2006; 43: 971-980.
26. Zizzo N, Patruno R, Zito FA, Di Summa A, Tinelli A, Troilo S, Misino A, Ruggieri E, Goffredo V, Gadaleta CD and Ranieri G. Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model. Leukemia and Lymphoma 2010; 1: 291-296.
27. Moehler TM, Ho AD, Goldschmidt H and Barlogie B. Angiogenesis in hematologic malignancies. Critical Reviews in Oncology/Hematology 2003; 45: 227-244.
28. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K and Fournel-Fleury C. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. The Veterinary Journal 2004; 16: 158-166.
29. Salven P, Teerenhovi L and Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 3167-3172.
30. Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A, Nakata K, Kogawa K, Koito K and Hareyama M. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 2004; 100: 356-365.
31. Dong M and Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006; 107: 4589-4596.